Press Releases

Fighting every day to free individuals — and the families who love them — from the harmful effects of muscle-debilitating diseases so they can live longer and grow stronger

Press Releases

  • Catalyst Pharmaceuticals Conducting Trial to Test Amifampridine Phosphate (FIRDAPSE®) in Children with Congenital Myasthenic Syndromes

    Statement from Catalyst: Amifampridine phosphate in CMS Clinical Trial

    Researchers are looking for children, ages 2 to 17 years, with congenital myasthenic syndrome (CMS) to participate in a new phase 3 study being conducted by Catalyst Pharmaceuticals to test the experimental drug amifampridine phosphate.

  • MDA Team Momentum Fights Back Against Neuromuscular Disease at the 2015 Marine Corps Marathon

    WASHINGTON, D.C., Oct. 20, 2015 — The Muscular Dystrophy Association’s nationwide endurance program MDA Team Momentum will make its second appearance at the 2015 Marine Corps Marathon on Oct. 25 to help support MDA’s mission to save and improve the lives of kids and adults fighting muscular dystrophy, ALS and related life-threatening diseases that severely limit muscle strength and mobility.

  • Enrollment in Diaphragm Pacing Systems for People with ALS Halted

    In September, the Data Safety and Monitoring Board (DSMB), constituted to oversee the Diaphragm Pacing System in Participants with Amyotrophic Lateral Sclerosis (DPS in ALS) study, being conducted in the United States, issued a recommendation that new enrollment be halted. At the same time, the DSMB recommended that patients already randomized to the diaphragm pacing arm continue to be actively stimulated and followed according to the protocol. 

  • MDA Awards $10 million in new Research Grants

    Record-breaking interest highlights progress, desire to find breakthroughs across diseases

     

    CHICAGO, August 25, 2015 – Powered by its big-picture perspective to accelerate treatments and cures across the broad spectrum of neuromuscular diseases, MDA today announced the award of $10 million in new research grants to the world’s brightest scientists conducting leading-edge discovery for muscular dystrophy, ALS and related muscle-debilitating diseases.

  • Marathon Pharmaceuticals Begins New Drug Application Process for Deflazacort to Treat Duchenne Muscular Dystrophy

    Following a pre-NDA meeting with the U.S. Food and Drug Administration (FDA), Marathon Pharmaceuticals has announced that it will begin the New Drug Application (NDA) process for deflazacort as a treatment for Duchenne muscular dystrophy (DMD).

    Marathon expects to submit the NDA in the first quarter of 2016. If the application is approved, the company could make the drug commercially available in the United States in the first quarter of 2017.

  • MDA Unites with the ALS Community as ALS Ice Bucket Challenge Returns

    In August 2014, the ALS Ice Bucket Challenge went viral on social media and swept the nation by storm. Individuals, groups, families, celebrities, politicians and athletes posted videos online of themselves participating in the phenomenon and challenging others to follow suit. Public awareness and donations to fight ALS soared to greater heights, and hope rose throughout the ALS community that this sensational social campaign could help us move closer than ever before to treatments and cures.

    Now it’s up to us to keep that momentum going.